Testing effectiveness (Phase 2)Study completedNCT03430895
What this trial is testing
Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract
Who this might be right for
Non-Transitional Cell Carcinoma of the Urothelial TractSmall Cell of the BladderAdenocarcinoma of the Bladder+2 more
Memorial Sloan Kettering Cancer Center 15